Company / Operating Cash Flow
Decoy Therapeutics Inc. Operating Cash Flow History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$10.2M
FY2022
5-year range
-$32.1M / $4.2M
FY2018-FY2022
Trend
+1.1%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 7 years, ranging from -$32M in FY2018 to $4M in FY2019.
Based on SEC 10-K filings.
-$10M in FY2022.
Improved from -$12M to -$10M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, operating cash flow increased 1.1% year-over-year.
- Peak operating cash flow was recorded in FY2019.
- Lowest operating cash flow in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | -$10.2M | +1.1% |
| FY2021 | -$10.3M | +11.0% |
| FY2020 | -$11.6M | -377.2% |
| FY2019 | $4.2M | +113.0% |
| FY2018 | -$32.1M | -54.5% |
| FY2017 | -$20.7M | -220.1% |
| FY2016 | -$6.5M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026